Cuthbert Ormond Simpkins

Vivacelle Bio, Inc.

$391,668

Attributed

$531,452

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $279.6K · FY2021–24

$500K$375K$250K$125K$0

'21

'22

'23

'24

Funding mix

By agency

NIH$531,452 · 2

By mechanism

R41$279,569 · 1

R43$251,883 · 1

Top collaborators

Michael Wacker1 shared

Most similar at Vivacelle Bio, Inc.

Same institution · by research overlap

Michael Wacker$139,785

Others in their field

Other Emerging Leaders on “Legal Patent”

Bala Raja · Luminostics, Inc.$28,624,460
Nikej Shah · Nirsum Laboratories, Inc.$12,588,496
Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$10,485,488
Laurie Lucas · Four Points Technology, Llc$9,526,424
Matthew Golden · Maphabit, Inc.$8,248,782
Ashkan Vaziri · Biosensics, Llc$7,399,204

Research focus

Legal PatentNitric OxideGrantIn VivoLiquid SubstanceNanoparticleCessation Of LifeFormulationHemorrhagic ShockInternationalLiposomesAqueousMicellesMortalityBloodBlood PressureDesignEnsureHemorrhageBiological AvailabilityInfusion ProceduresBiomaterial CompatibilityLifeOrgan

Grant awards (2)

Development of VBI-1 as a novel treatment protocol for outpatient cardiac arrest$279,569

R41 · FY2024 · HL · contact PI

Nitric Oxide redistribution by a phospholipid nanoparticle colloid to treat septic shock.$251,883

R43 · FY2021 · GM · contact PI